A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

NCT04227015 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Non-hodgkin Lymphoma

Interventions

DRUG: CTA101

Sponsor

He Huang

Collaborators

[object Object]